FDA
-
-
-
-
-
-
-
Surface (SURF) and VIB Report Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
-
-
-
-
-
-
-
Surface Oncology (SURF) Reports Q1 EPS of $0.13, Provides Corporate Highlights
-
-
-
-
-
-
-
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021
-
-
-
-
-
-
-
Surface Oncology (SURF) Announces SRF388 Demonstrates Monotherapy Activity in Data Presented at American Society of Clinical Oncology Annual Meeting
-
-
-
-
-
-
-
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting
-
-
-
-
-
-
-
Surface Oncology (SURF) to Collaborate with Merck (MRK) on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors
-
-
-
-
-
-
-
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020
-
251,615 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All